NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading INMB? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. INMB is focused on advancing treatments for conditions like Alzheimer's disease and rare diseases, but it is currently loss-making and faces high risk.
The market has priced in a high valuation premium compared to peers, reflecting expectations for future breakthroughs. However, the valuation is considered fragile due to the company's current losses and the high-risk environment.
Management is working on key priorities, including advancing XPro1595 and CORDStrom, but recent changes in risk assessment indicate potential challenges. The company has a mixed status on its management priorities, which could impact future performance.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as well as the Federal Reserve's interest rate decisions. Positive developments in these areas could provide a favorable environment for INMB.
Overall, INMB's trajectory will depend on its ability to navigate regulatory processes and market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Starting this trial is crucial for XPro1595's path to market in early Alzheimer's disease.
Confirms:The company announces the start of the Phase 2b/3 trial for XPro1595.
Disproves:The company delays the Phase 2b/3 trial start beyond the expected timeline.
Why it matters: Progress on this partnership could drive growth and validate the company's strategy.
Confirms:A press release will share new updates or milestones in the partnership.
Disproves:No updates or negative news regarding the partnership in the next quarter.
Why it matters: If peers like Lilly or AbbVie show strong performance, it could impact Inmune Bio's outlook.
Confirms one read:Lilly or AbbVie post quarterly results showing revenue growth above 10%.
Confirms the other:Lilly or AbbVie report revenue declines or weak guidance.
Why it matters: If health care revenue grows faster again, it may mean a change for Inmune Bio.
Confirms:Health care revenue growth goes back to 10% or more.
Disproves:Health care revenue growth continues to decelerate below 10%.
Why it matters: A successful change could help how money is used and boost investor trust.
Confirms:An announcement will confirm the successful change of the April 2024 Warrants.
Disproves:Failure to amend the warrants or negative feedback from investors.
Why it matters: The results may show XPro1595 works well. This could help its approval process.
Confirms:The company presents positive results from the MINDFuL trial at AAIC 2026.
Disproves:The company shows poor or unclear results from the MINDFuL trial.
Why it matters: This submission is a key step for CORDStrom in treating RDEB. It could open new revenue streams if approved.
Confirms:The company files the UK MAA for CORDStrom in 2026 as planned.
Disproves:The company delays the UK MAA submission beyond 2026.
